LZAGF News and Press, Lonza Group AG From 02/11/24

2024-02-11 12:00:03 ET More on Eli Lilly, Novo Nordisk, etc. Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly and Co (LLY) Q4 2023 Earnings Conference Call Transcript ...

2024-02-05 15:46:06 ET More on Catalent, Novo Nordisk, etc. Novo Nordisk A/S (NVO) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Novo Nordisk: Outlook For Weight Loss Drugs In 2024 Biggest stock movers today: Nvidia, Air Product...

2024-01-27 10:40:00 ET Summary Lonza Group aims to increase revenue by double digits by 2028 through aggressive expansion in the CDMO space. Lonza expects to increase its EBITDA margin to 32%-34% by 2028 and maintain a low debt ratio. The company plans to generate 25% of its r...

2024-01-26 13:14:05 ET Lonza Group AG (LZAGY) Q4 2023 Earnings Conference Call January 26, 2024, 08:00 AM ET Company Participants Albert Baehny - CEO ad Interim and Chairman of the Board of Directors Philippe Deecke - CFO Conference Call Participants Rich...

2024-01-26 11:52:39 ET More on Lonza Lonza not planning to manufacture GLP-1 drugs: report Historical earnings data for Lonza Group Dividend scorecard for Lonza Group Financial information for Lonza Group Seeking Alpha’s Quant Rating on Lonza G...

2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...

2023-10-16 10:34:11 ET More on Vaxcyte Strong Financials And Pipeline Position Vaxcyte For Success Seeking Alpha’s Quant Rating on Vaxcyte Historical earnings data for Vaxcyte Financial information for Vaxcyte For further details see: Vaxcy...

2023-10-05 04:55:58 ET Summary Lonza's CEO departure raises questions about business continuity, but we believe the stock price already reflects the worst-case scenario. Lower CAPEX and an ongoing buyback program (with potential M&A flexibility) are a plus given a 'higher for ...

2023-09-24 12:00:08 ET More on COVID vaccine makers Moderna: Covid Curse Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases Novavax: Sell A Covid Bounce Barclays projects over $5B COVID booster sales in fall 2023 Vaccine makers...

2023-09-19 10:56:26 ET More on Moderna Moderna: Buy Before The Fall Covid-19 Wave Moderna slips 8% as Pfizer COVID shot forecast weighs on shares Pfizer sees 24% of eligible Americans getting COVID-19 boosters Pfizer, Moderna And COVID Vaccine Patents: Implic...